RT Journal Article
T1 [Recommendations of the Spanish Society of Paediatric Cardiology and Congenital Heart Disease as regards the use of drugs in attention deficit hyperactivity disorder in children and adolescents with a known heart disease, as well as in the general paediatric population: Position statement by the Spanish Paediatric Association].
T2 Recomendaciones de la Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas en relación con el uso de medicamentos en el trastorno por déficit de atención e hiperactividad en niños y adolescentes con cardiopatías conocidas y en la población pediátrica general, posicionamiento de la Asociación Española de Pediatría.
A1 Pérez-Lescure Picarzo, Javier
A1 Centeno Malfaz, Fernando
A1 Collell Hernández, Rosa
A1 Crespo Marcos, David
A1 Fernández Soria, Teresa
A1 Manso García, Begoña
A1 Rojo Sombrero, Henar
A1 Sabaté Rotés, Anna
A1 Sarquella-Brugada, Georgia
K1 Acquired heart disease
K1 Atomoxetina
K1 Atomoxetine
K1 Cardiopatías adquiridas
K1 Cardiopatías congénitas
K1 Cardiovascular side effects
K1 Congenital heart defects
K1 Efectos secundarios cardiovasculares
K1 Guanfacina
K1 Guanfacine
K1 Lisdexamphetamine
K1 Lisdexanfetamina
K1 Methylphenidate
K1 Metilfenidato
K1 Muerte súbita
K1 Sudden death
AB Approved drugs for attention deficit hyperactivity disorder (ADHD) in Spain are methylphenidate, lisdexamphetamine, atomoxetine and guanfacine. Due to adverse cardiovascular effects, mainly increased blood pressure and heart rate, its use in patients with known or undiagnosed heart disease may be controversial. To obtain a consensus document from the Spanish Society of Paediatric Cardiology and Congenital Heart Diseases (SECPCC) and experts from other Agencies and Societies as a guide for the paediatric cardiologist and physicians who treat children and adolescents with ADHD. An analysis was performed on the bibliography and Clinical Practice Guidelines, technical data sheets approved by the Spanish Agency of Medicines and Health Devices, and the Spanish Ministry of Health Guidelines. A Working Group was formed, with a Coordinator, as well as members of the Clinical Cardiology Working Group and Arrhythmia Group of the SECPCC. This Group produced a preliminary document that was reviewed by a group of external experts and a group of internal experts of the SECPCC with a consensus being reached on the final document. The recommendations of the SECPCC and the group of experts are presented on cardiovascular evaluation prior to treatment in children and adolescents with no known cardiovascular disease and with known cardiovascular disease. The recommendations of the SECPCC and the group of experts are also presented on the use of medications for ADHD in children and adolescents with cardiological symptoms with no evidence of heart disease, congenital heart disease, cardiomyopathy, Marfan syndrome and other aortic diseases, hypertension, and arrhythmias.
YR 2019
FD 2019-10-30
LK http://hdl.handle.net/10668/14619
UL http://hdl.handle.net/10668/14619
LA es
DS RISalud
RD Apr 17, 2025